Doctors in California said on June 30 that they have completed the first procedure in which a patient’s own heart tissue was used to grow specialized stem cells that were then injected back into the heart to repair and re-grow healthy muscle that had been injured by a heart attack.
The minimally-invasive procedure was completed at the Cedars-Sinai Heart Institute (Los Angeles, Calif.) on June 26.
The procedure is part of a Phase I investigative study approved by the U.S. Food and Drug Administration and supported by the Specialized Centers for Cell-based Therapies at the National Heart, Lung, and Blood Institute and the Donald W. Reynolds Foundation.
It is the first to use adult cells from a patient’s own heart to attempt to heal injured heart muscle.
“This procedure signals a new and exciting era in the understanding and treatment of heart disease,” said Eduardo Marban, M.D., Ph.D., director of the Cedars-Sinai Heart Institute, who developed the technique and is leading the clinical trial. “Five years ago, we didn’t even know the heart had its own distinct type of stem cells. Now we are exploring how to harness such stem cells to help patients heal their own damaged hearts.”
The study is directed by the Cedars-Sinai Heart Institute, with the collaboration of the Johns Hopkins University, where Marban worked prior to joining Cedars-Sinai in 2007.
The 24 patients participating in the study have hearts that were damaged and scarred by heart attacks. Once enrolled in the study, patients go through a three-step procedure.
After undergoing extensive imaging so doctors can pinpoint the exact location and severity of the scars wrought by the heart attack, the patient undergoes a minimally-invasive biopsy, with local anesthesia.
Using a catheter inserted through a vein in the patient’s neck, doctors remove a small piece of heart tissue, about half the size of a raisin.
The heart tissue is then taken to a specialized lab at Cedars-Sinai, where heart stem cells are cultured using methods invented by Marban and his team. It takes about four weeks for the cells to multiply to numbers sufficient for therapeutic use, approximately 10 to 25 million.
In the third and final step, the now-multiplied stem cells are re-introduced into the patient’s coronary arteries during a second catheter procedure.
All patients in the study had to have experienced heart attacks within four weeks prior to enrolling in the research project. Four patients will receive 12.5 million stem cells and two patients will serve as controls.
Later this summer, it is anticipated that 12 more patients will undergo procedures to receive 25 million stem cells, while six additional patients will be monitored as controls.
The first patient experienced a heart attack on May 10 due to a 99 percent blockage in the left anterior descending artery, a major artery of the heart.
The heart attack left 21 percent of his heart muscle infarcted, or scarred. He underwent his biopsy May 24 and received his infusion of stem cells on June 29.
The patients will be monitored for six months. Complete results are scheduled to be available in late-2010.
Marban said the cardiac stem cell procedure is a logical step forward from recent studies in which cardiac patients have been treated with stem cells derived from bone marrow.
Studies over the past eight years have shown that more than 500 cardiac patients have experienced modest improvement when treated with bone marrow stem cells.
However, bone marrow stem cells are not predestined to regenerate heart muscle.
When cardiac stem cells were discovered five years ago by various teams worldwide, Marban began developing a method for isolating heart stem cells from minimally-invasive biopsies and then multiplying the cells.
Unlike bone marrow cells, heart stem cells are naturally programmed to regrow heart tissue, so they could prove more effective in healing the injury caused by heart attacks.
“If successful, we hope the procedure could be widely available in a few years and could be more broadly applied to cardiac patients,” Marban said.
For example, if patients are able to re-grow damaged heart muscle via stem cell therapy, there could be lesser demand for expensive and risky treatments such as heart transplants.
The process to grow the cardiac-derived stem cells involved in the study was developed by Marban when he was on the faculty of Johns Hopkins University.
The university has filed for a patent on that intellectual property, and has licensed it to a company in which Marban has a financial interest.
No funds from that company were used to support the clinical study.
All funding was derived from the National Institutes of Health, the Donald W. Reynolds Foundation and Cedars-Sinai Medical Center.
Contact: Eduardo Marban, http://www.csmc.edu/13808.html
...
For many years we have provided stem cell-related news and
analysis free of charge on this Web Site, supported by
advertising and subscription income. Unfortunately, in today’s
economy, advertising placements are at an all-time low. That has
forced us (and other publishers) to seek income elsewhere.
Hence, the subscription fees for premium content.
1) You read about stem cell research you'll never hear about
in the general press, and you'll get the complete article, not just a snippet.
2) Important references are clickable links. (e.g., a
reference to a research institution
or researcher's lab site or more
information about a disease or disorder
are highlighted and clickable as Web links.)
3) Full citations are provided for all journal articles
so you can access the original research.
4) Links to article abstracts are provided.
5) Links to researcher e-mail addresses and lab Web sites
are provided whenever available.
6) Graphic images are provided when available.
7) Links to Related Articles in our database of more than
2,000 stem cell research articles.
